United States Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Trends and Insights

Rising MASH Therapy-Linked Fibrosis Testing Demand

The FDA approval of resmetirom in March 2024 created the first clear therapy-linked testing pathway for patients with non-cirrhotic MASH and moderate-to-advanced fibrosis. Because prescribing moved into real clinical practice without a universal biopsy requirement, blood-based and imaging-based tests became the practical gatekeepers for treatment eligibility in the United States NASH biomarkers market. That shift matters because a therapy decision now drives biomarker demand directly, rather than leaving testing tied mainly to specialist workups or clinical trials. As additional MASH therapies move closer to commercialization, each approval will widen the pool of patients needing non-invasive staging and repeat reassessment. This makes growth in the United States NASH biomarkers market cumulative, since every new treatment adds another layer of testing demand across diagnosis, access, and follow-up.

Guideline-Backed Non-Invasive Triage Pathways

The AASLD January 2025 guidance established FIB-4 as the preferred first-tier blood-based test for advanced fibrosis assessment, with ELF used as a sequential marker, which gave clinicians a national framework for structured triage. The same guidance stated revised FIB-4 thresholds and reported pooled specificity of 0.94 for ruling in advanced fibrosis, which supports broader use across primary care, endocrinology, and gastroenterology. AASLD also advised against using blood-based markers for tracking fibrosis progression over time, which leaves room for imaging platforms to expand within the monitoring portion of the United States NASH biomarkers market. The EASL-EASD-EASO 2024 guideline reinforced this direction through a multi-step pathway based on FIB-4, followed by elastography, and it also recognized NIS2+ for identifying at-risk MASH. Together, these documents reduce pathway ambiguity for large health systems and make testing volumes more durable even as the competitive mix of panels and platforms continues to change.

Pharma And CRO Biomarker-Enrichment Spending

MASH trials still depend heavily on biomarker-guided enrichment because biopsy-confirmed enrollment is slow, expensive, and inefficient without pre-selection tools. Labcorp stated that its MASH platform supported 31 active MASLD and MASH studies across more than 700 global trial sites and enrolled over 4,000 biopsy-confirmed patients, which shows the scale of sponsor reliance on biomarker-linked screening infrastructure. The FDA qualification of PathAI's AIM-MASH AI Assist in December 2025 added another efficiency layer by allowing more standardized histologic scoring support for Phase 2 and Phase 3 trials. Sponsors are also funding multiple non-invasive readouts in parallel, which raises per-trial biomarker spending even when the same program still uses biopsy endpoints. As a result, the pharma channel gives the United States NASH biomarkers market a revenue stream that is less dependent on near-term commercial prescribing and more tied to pipeline depth^{[1]Labcorp, “Testing for MASH and MASLD,” Labcorp, labcorp.com}.

Demand For Repeatable Biopsy-Sparing Monitoring

Liver biopsy remains the histologic reference standard, but its risk profile makes repeated use difficult for patients who may need reassessment every 6 to 24 months during therapy. AASLD reported procedure-related bleeding in 0.2% of cases, severe bleeding in 0.01%-0.04%, and mortality in 0.0083%-0.01%, which underscores why repeat monitoring is moving toward non-invasive tools. The FDA acceptance of Echosens' Letter of Intent in September 2025 for FibroScan VCTE as a reasonably likely surrogate endpoint raised the strategic value of liver stiffness measurement for both trials and future care pathways. Perspectum also reported that an 80 ms reduction in cT1 predicted histological response in pooled interventional trial data, which gives imaging-based monitoring a practical benchmark for treatment follow-up. This supports a monitoring model in the United States NASH biomarkers market that can scale with therapy use without running into biopsy scheduling, patient tolerance, or procedural capacity limits^{[2]Echosens, “Statement on the Acceptance by the FDA of Echosens’ Letter of Intent for Drug Development Tool,” Echosens, echosens.com}.

Uneven Payer Reimbursement For Proprietary Panels

Commercial momentum has outpaced reimbursement alignment for many proprietary biomarker panels in the United States NASH biomarkers market. Blue Cross Blue Shield of Tennessee has excluded several hepatic fibrosis panels from coverage, while CMS proposed a MolDX framework that limits coverage to settings where FIB-4 and imaging elastography are indeterminate. In 2026, CMS established an initial pricing framework for NASHnext, but GENFIT described that step as an early milestone rather than full reimbursement maturity^{[3]GENFIT, “GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update,” Euronext, live.euronext.com}. Emerging molecular and proteomic tests also face CLIA and MolDX technical assessment requirements before they can scale, which slows onboarding even when analytical performance is promising. This leaves developers with demand visibility but uneven revenue realization, especially when payer policy still favors simpler first-line pathways before proprietary panels are considered.

Biopsy Still Anchors Some Confirmatory Decisions

Non-invasive testing has expanded quickly, but biopsy still anchors some confirmatory and treatment decisions across important care settings. Perspectum cited the United States Department of Veterans Affairs as still requiring liver biopsy confirmation for resmetirom prescribing under current institutional guidance, which keeps a major integrated system on a more procedural pathway. AASLD also advised against using blood-based non-invasive tests for tracking fibrosis progression or regression over time, which preserves a role for biopsy or imaging escalation in follow-up decisions. The same guideline noted that many patients fall into indeterminate FIB-4 ranges, which means some care pathways still require imaging or tissue confirmation before a final decision is made. Even as AI-assisted pathology improves standardization, the continued clinical role of biopsy slows full substitution and keeps parts of the United States NASH biomarkers market tied to hybrid diagnostic workflows.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Biomarker Class: Fibrosis Panel Dominates, Metabolomics Gains Speed

Direct fibrosis biomarkers held 33.31% of the United States NASH biomarkers market size in 2025, which reflects their established role in specialist workups, risk stratification, and trial screening. This lead rests on the broad clinical familiarity of FIB-4, ELF, PRO-C3, and proprietary composite panels that are already embedded in hepatology practice and trial design. AASLD and EASL guidance supports that position because both frameworks place fibrosis-oriented tools early in the patient pathway, which keeps them close to referral and treatment decisions. Siemens Healthineers strengthened this class through automated ELF availability on Atellica IM and ADVIA Centaur systems, and Roche added routine lab scalability with the Elecsys PRO-C3 launch on cobas. Hepatocyte injury and apoptosis markers such as CK-18 and M30 remain relevant in exploratory and CRO settings, but their routine clinical pathway is still less established than fibrosis-focused tests in the United States NASH biomarkers industry.

Metabolic and lipidomic biomarkers are projected to expand at a 26.38% CAGR through 2031, which makes them the fastest-growing class within the United States NASH biomarkers market. OWLiver and related lipid-based approaches have shown clinically useful discrimination of at-risk MASH through combined lipid profiling and metabolic variables, which improves their relevance for upstream case finding. Proteomic models have also advanced quickly, with a serum protein risk score and broader multi-protein signatures posting strong validation performance across fibrosis stages. Inflammatory markers and genomic panels are still more common in enrichment and response-prediction work, where sponsors value multi-analyte depth even before routine reimbursement is available. Imaging biomarkers remain the most regulation-sensitive modality in the United States NASH biomarkers industry, because FDA movement on FibroScan VCTE and cT1 directly affects how monitoring tools compete with blood-based panels.

By Application: Diagnosis Leads, Monitoring Expands Fast

Clinical diagnosis and staging accounted for 42.24% of the United States NASH biomarkers market size in 2025, which reflects the immediate need to identify fibrosis stage before treatment initiation and specialist referral. Resmetirom's launch made this application commercially central because treatment access now depends on documenting disease severity through biopsy-free pathways whenever clinically acceptable. The opportunity remains large because millions of Americans are estimated to carry moderate-to-advanced scarring, while many eligible patients still remain outside structured hepatology evaluation. Screening and secondary risk stratification also matter because panels such as NIS2+ and NASHnext are designed to identify at-risk patients earlier in the care pathway, before hepatology referral becomes necessary. AASLD's endorsement of FIB-4 as a first-line screen broadened the testing base beyond liver specialists and widened the top of the funnel across primary care and endocrinology.

Therapeutic monitoring and response assessment is forecast to grow at a 28.52% CAGR from 2026 to 2031, which makes it the structural growth engine of the United States NASH biomarkers market. The case for this segment is straightforward because patients on therapy need repeat assessment of treatment effect, while repeated biopsy remains difficult to justify clinically and operationally. Perspectum reported that an 80 ms reduction in cT1 predicted histological response, which gives imaging-based monitoring a measurable threshold that clinicians and drug developers can use. Prometheus Laboratories also presented a next-generation blood-based non-invasive test at DDW 2026 that is intended to address both treatment-eligible patient identification and longitudinal monitoring. Academic and epidemiologic applications remain smaller in revenue terms, but they still help novel biomarker classes build the evidence base needed for later clinical adoption across the United States NASH biomarkers market.

By End User: Hospitals Drive Revenue, Reference Labs Gain Scale

Hospitals and clinics represented 34.52% of the United States NASH biomarkers market size in 2025, because they remain the main setting for hepatology consultation, elastography access, and treatment prescribing. Large health systems have an advantage when they embed liver disease pathways into routine metabolic care, since automated FIB-4 screening can convert high-risk patient populations into repeat biomarker testing demand. The NAFLD Clinical Care Pathway trial in VA primary care illustrates this logic, because it tests a structured referral and triage approach rather than relying on isolated physician behavior. Hospitals also benefit from being close to the treatment decision point, which lets them connect staging, counseling, imaging, and prescribing within one workflow. The pharma and CRO end-user group is smaller by revenue share, but it places the highest demands on reproducibility, qualification status, and platform compatibility.

Diagnostic laboratories and reference labs are projected to grow at a 26.25% CAGR through 2031, which reflects their scale economics and standardized assay infrastructure. High-throughput labs can run automated ELF, PRO-C3, and composite panels more efficiently than lower-volume hospital laboratories, which gives them an advantage as testing broadens. Their position is likely to strengthen as CMS reimbursement frameworks mature and prior authorization workflows become more standardized for clinically supported panels such as NASHnext. National lab networks also reach community practices more efficiently, which matters because much of the untreated patient pool sits outside academic hepatology centers. Academic institutes and public research programs contribute smaller volumes, but they remain important for validating the next generation of candidate markers that may later enter commercial testing menus.

Geography Analysis

The United States non-alcoholic steatohepatitis (NASH) biomarkers market covers the full national care system, but internal demand is uneven because disease burden, specialist density, and testing infrastructure vary sharply by region. The South and Appalachia carry a heavier metabolic liver disease burden, and the user-supplied analysis noted that MASLD affects 35-48% of the United States adult population while rates are especially elevated among Hispanic individuals concentrated in Texas, California, Florida, and the Southwest. This creates a pattern where clinical need is very high in several large population centers, yet standardized biomarker deployment is still uneven across lower-resource provider settings. The Veterans Health Administration represents a distinct sub-market because metabolic risk is common in the Veteran population and testing pathways can be scaled nationally once a clinical rule is set. A 2025 study in BMC Health Services Research found that only 10% of Veterans with elevated FIB-4 received a cirrhosis diagnosis, which points to a large pool of under-identified advanced disease that structured triage could surface.

The Northeast corridor shows the highest adoption intensity within the United States NASH biomarkers market because it combines dense hepatology capacity, strong academic referral networks, and a high concentration of CRO and pharma trial activity. Boston, New York, Philadelphia, and Baltimore stand out as centers where health systems can connect blood testing, imaging, biopsy review, and trial enrollment with less pathway fragmentation. The Midwest also performs strongly because academic hepatology programs and centralized laboratory workflows support national specimen routing from lower-density geographies into high-complexity testing platforms. This centralization matters because it lets regional demand convert into billable testing volume even when local specialist supply is limited.

The West Coast has become an important technology adoption cluster for the United States NASH biomarkers market because AI pathology, imaging analytics, and digital workflow companies are closely linked to trial sites and tertiary liver centers. California and the Pacific Northwest are particularly relevant for imaging-based monitoring adoption, since tertiary centers in these geographies are more likely to use advanced MRI-based liver assessment. At the same time, the VA biopsy requirement remains a large institutional barrier to wider biomarker adoption across its 170+ medical centers, which delays volume conversion in an otherwise high-need national network. These patterns keep the market national in scope but highly localized in realized commercial volume, with hepatology hubs and reference laboratory corridors leading early uptake.